Estudios estructurales de relaxasas involucradas en el proceso de conjugación bacteriana

La transferencia horizontal genética en bacterias se produce mediante tres procesos principales: transformación, transducción y conjugación. Este último proceso es considerado uno de los mecanismos más relevantes en la evolución bacteriana y se caracteriza por su eficiencia en la adquisición de nuevos rasgos adaptativos, como ser la resistencia a antibióticos. Existen dos tipos de plásmidos que pueden ser transferidos mediante el proceso de conjugación: conjugativos y movilizables. Los conjugativos son auto-transmisibles ya que codifican todas las proteínas necesarias para la formación del sistema de secreción (ej. F y R388 de Escherichia coli). Los movilizables, por el contrario, son solo transmisibles en presencia de funciones conjugativas adicionales (ej. pMV158 de Streptococcus agalactiae). El proceso de conjugación se inicia con el corte de un enlace específico fosfo-diéster del ADN a ser transferido mediante una proteína denominada relaxasa. Es el caso de la proteína TrwC del plásmido conjugativo R388, cuyos estudios bioquímicos y estructurales demostraron que la presencia de una tríada de histidina, coordinada a un ión metálico, y dos residuos tirosina juegan un rol decisivo en el mecanismo catalítico. Un estudio sistemático, por difracción de rayos X ha permitido determinar la identidad y función del ión metálico, la localización de la segunda tirosina catalítica y la posición del grupo fosfato del enlace fosfo-diéster a ser cortado. Asimismo, se caracterizó por difracción de rayos X, la proteína MobM del plásmido movilizable pMV158. Esta proteína cumple un papel homólogo al de la TrwC, pero en una bacteria Gram positiva. La estructura cristalina de MobM es la primera obtenida de una relaxasa implicada en el sistema de movilización de una bacteria Gram positiva. Las similitudes y diferencias estructurales se describirán en este informe.

Epidemiologia de la Peritonitis Bacteriana Espontània en el nostre medi

Objectius: . Descriure l’epidemiologia de les PBE del nostre hospital. Material i Mètodes: S’analitzen les característiques de les PBE diagnosticades entre 2007-2010. Resultats: S’identificaren 44 episodis (73% extrahospitalàries). La taxa de cultius positius fou del 52% (52%BGN; 34%CGP). S’observà : 18% d’Escherichia coli amb resistència a quinolones; 57% de Klebsiella spp BLEA. Aparegué insuficiència renal en un 20%. La mortalitat fou del 27%. Conclusions: No s’observà una major proporció de CGP en el grup nosocomial. La resistència a quinolones i la producció de BLEA és inferior a la reportada. La mortalitat fou superior en el grup nosocomial.

Evolución clínica y pronóstico de la ascitis neutrocítica con cultivo negativo (ANCN) y la peritonitis bacteriana espontánea (PBE)

263 pacients cirròtics que van presentar la primera descompensació ascítica es van seguir de forma prospectiva. A tots els pacients se’ls va realitzar anàlisi del líquid ascític. 58 pacients van desenvolupar 83 episodis d’infecció del líquid ascític. En 44 episodis el cultiu va ser negatiu i en 37 va ser positiu. A l’ingrès, els pacients amb ANCN van presentar una funció hepàtica i renal millor que aquells amb ANCN. La infecció del líquid ascític es va resoldre més precoçment als pacients amb ANCN, amb una menor incidència d’insuficiència renal. Es va observar una tendència a presentar una menor mortalitat acumulada a l’any al grup de pacients amb ANCN. La ANCN apareix sobretoto en cirròtics amb una malaltia hepàtica menys evolucionada.

Análisis de las bacterias responsables y resistencias a antibióticos en la peritonitis bacteriana espontánea

L’objectiu de l’estudi és analitzar el tipus de bactèries aïllades en pacients amb peritonitis bacteriana espontània (PBE) i la seva sensibilitat antibiòtica en dos períodes de temps (gener 2001- juny 2004 i juliol 2004- desembre 2007). No hem observat un augment de cocs Gram-positius com a responsables de la PBE ni de resistències bacterianes en els últims anys. Les bactèries causants de PBE intrahospitalàries o en pacients en profilaxi amb norfloxací presenten un elevat percentatge de resistències a les cefalosporines de tercera generació, per tant en aquests pacients es podria valorar com a primera opció terapèutica empírica un carbapenem.

Insuficiència renal i mortalitat dels pacients cirròtics amb peritonitis bacteriana espontània i baix risc de mortalitat no tractats amb albúmina

L’expansió amb albúmina disminueix la incidència d’insuficiència renal i la mortalitat dels pacients cirròtics amb peritonitis bacteriana espontània (PBE). Però no està ben establert si caldria administrar-la a tots aquests pacients. Aquest estudi determina la incidència i evolució de la insuficiència renal i mortalitat en una sèrie no seleccionada de pacients cirròtics amb PBE i baix risc de mortalitat (urea&11mmol/l i bilirrubina&68µmol/l) no tractats amb albúmina. La baixa mortalitat i la bona evolució de la funció renal observades en els pacients amb PBE i baix risc de mortalitat no tractats amb albúmina, suggereixen que en aquests pacients no caldria administrar albúmina.

Estudio caso-control de las cefalosporinas como tratamiento empírico de la peritonitis bacteriana espontánea en los receptores de trasplante hepático ortotópico. Epidemiología e impacto en la mortalidad

La peritonitis bacteriana espontánea consiste en la infección del líquido ascítico en ausencia de un foco evidente intraabdominal. Los microorganismos causales más frecuentes son bacilos Gram negativos y cocos Gram positivos. Son escasos los datos en los pacientes trasplantados hepáticos que evolucionan a cirrosis. Se diseñó un estudio caso-control con el objetivo de determinar la idoneidad del tratamiento empírico con ceftriaxona en dicha población. No se observaron diferencias etiológicas entre ambos grupos y la sensibilidad a cefalosporinas de tercera generación fue similar. Los trasplantados presentaron mayor incidencia de insuficiencia renal, y mayor mortalidad durante el episodio y a 6 meses.

Diversitat bacteriana a les esponges marines

L’objectiu principal del projecte era aprofundir en el coneixement de les malalties de les esponges, centrant-nos en la diversitat bacteriana que acullen. Als estius 2008 i 2009 va haver episodis d’elevades temperatures de l’aigua de mar que van suposar importants mortalitats massives d’esponges a la Mediterrània. Contra tot pronòstic, els estius del projecte, el 2010 i el 2011, no van resultar especialment calorosos i no hi va haver episodis de mortalitat. És un fet molt positiu per les comunitats bentòniques però algun dels objectius específics de la meva proposta no es va poder dur a terme com havien estat platejats inicialment. Disposàvem de diferents mostres d’esponges malaltes de l’espècie Ircinia fasciculata, sanes i aigua circumdant recollides l’estiu 2009 i fixades per DNA, per això s’han pogut identificar i caracteritzar els canvis en la comunitat microbiològica de les esponges malaltes respecte de les sanes. Hem constatat que més que una infecció per un o pocs patògens puntuals, com havien proposat alguns autors, hi ha un canvi dràstic en la comunitat microbiològica associada a les esponges. Les esponges malaltes, on dominen els bacteris heterotròfics, presenten una major diversitat bacteriana que les sanes, on dominen els autòtrofs. Tot i que no es va poder realitzar un nou mostreig d’individus malalts, i algun objectiu específic no es va poder desenvolupar, vaig aprofitar l’estada en un centre de referència en estudis de la diversitat microbiana, per ampliar el coneixement general de les comunitats bacterianes associades a esponges. Es van realitzar nous estudis en què vam testar si totes les esponges (bacteriosponges i no) presenten simbionts reals o si les no-bacteriosponges presenten un enriquiment de les comunitats de l’aigua de mar però no una flora específica. El resultat és que totes les esponges presenten associacions molt específiques malgrat hi ha fortes diferències entre les comunitats microbianes associades a bacteriosponges i a no-bacteriosponges.

Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminary prospective observational study

BackgroundIn adult population with community acquired pneumonia high levels of pro-adrenomedullin (pro-ADM) have been shown to be predictors of worse prognosis. The role of this biomarker in pediatric patients had not been analyzed to date. The objective of this study is to know the levels of pro-ADM in children with community acquired pneumonia (CAP) and analyze the relation between these levels and the patients¿ prognosis.FindingsProspective observational study including patients attended in the emergency service (January to October 2009) admitted to hospital with CAP and no complications at admission. The values for pro-ADM were analyzed in relation to: need for oxygen therapy, duration of oxygen therapy, fever and antibiotic therapy, complications, admission to the intensive care unit, and length of hospital stay. Fifty patients were included. Ten presented complications (7 pleural effusion). The median level of pro-ADM was 1.0065¿nmol/L (range 0.3715 to 7.2840¿nmol/L). The patients presenting complications had higher levels of pro-ADM (2.3190 vs. 1.1758¿nmol/L, p¿=¿0.013). Specifically, the presence of pleural effusion was associated with higher levels of pro-ADM (2.9440 vs. 1.1373¿nmol/L, p¿<¿0.001).ConclusionsIn our sample of patients admitted to hospital with CAP, pro-ADM levels are related to the development of complications during hospitalization.

Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?

Although bacteremic pneumococcal pneumonia is the most severe form of pneumonia, non-bacteremic forms are much more frequent. Laboratory methods for the diagnosis of nonbacteremic pneumococcal pneumonia have a low sensitivity and specificity, and therefore all-cause pneumonia has been proposed as a suitable outcome to evaluate vaccination effectiveness. This work reviews the epidemiology of community-acquired pneumonia (CAP) and evaluates the effectiveness of the 3-valent pneumococcal polysaccharide vaccine (PPV-23) in preventing CAP requiring hospitalization in people aged ≥65 years. We performed a case-control study in patients aged ≥65 years admitted through the emergency department who presented with clinical signs and symptoms compatible with pneumonia. Weincluded 489 cases and 1,467 controls and it was obtained a vaccine efectiveness of 23.6 (0.9-41.0). Our results suggest that PPV-23 vaccination is effective and reduces hospital admissions due to pneumonia in the elderly, strengthening the rationale for vaccination programmes in this age group.

Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?

Although bacteremic pneumococcal pneumonia is the most severe form of pneumonia, non-bacteremic forms are much more frequent. Laboratory methods for the diagnosis of nonbacteremic pneumococcal pneumonia have a low sensitivity and specificity, and therefore all-cause pneumonia has been proposed as a suitable outcome to evaluate vaccination effectiveness. This work reviews the epidemiology of community-acquired pneumonia (CAP) and evaluates the effectiveness of the 3-valent pneumococcal polysaccharide vaccine (PPV-23) in preventing CAP requiring hospitalization in people aged ≥65 years. We performed a case-control study in patients aged ≥65 years admitted through the emergency department who presented with clinical signs and symptoms compatible with pneumonia. Weincluded 489 cases and 1,467 controls and it was obtained a vaccine efectiveness of 23.6 (0.9-41.0). Our results suggest that PPV-23 vaccination is effective and reduces hospital admissions due to pneumonia in the elderly, strengthening the rationale for vaccination programmes in this age group.

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.

Abstract Background: Tigecycline, an expanded broad-spectrum glycylcycline, exhibits in vitro activity against many common pathogens associated with community-acqui red pneumonia (CAP), as well as penetration into lung tissues that suggests effectiveness in ho spitalized CAP patients. The aim of the present study was to compare the efficacy and safety of intravenous (IV) tigecycline with IV levofloxacin in hospitalized adults with CAP. Methods: In this prospective, double-blin d, non-inferiority phase 3 trial, eligible patients with a clinical diagnosis of CAP supported by radiographic evidence were stratified by Fine Pneumonia Severity Index and randomized to tigecycline or levofloxacin for 7-14 days of therapy. Co-primary efficacy endpoints were clinical response in the clinically evaluable (CE) and clinical modified intent- to-treat (c-mITT) populations at te st-of-cure (Day 10-21 post-therapy). Results: Of the 428 patients who received at least on e dose of study drug, 79% had CAP of mild-moderate severity according to their Fine score. Clinical cure rates for the CE population were 88.9% for tigecycline and 85.3% for levofloxac in. Corresponding c-mITT population rates were 83.7% and 81.5%, respectively. Eradication rates for Streptococcus pneumoniae were 92% for tigecycline and 89% for levofloxac in. Nausea, vomiting, and diarrhoea were the most frequently reported adverse events. Rates of premature disc continuation of study drug or study withdrawal because of any adverse event were similar for both study drugs. Conclusion: These findings suggest that IV tigecycline is non-inferior to IV levofloxacin and is generally well-tolerated in the treatment of hospitalized adults with CAP.

Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone

Empirical antibiotic therapy of community-acquired pneumonia (CAP) has been complicated by the worldwide emergence of penicillin resistance among Streptococcus pneumoniae. The impact of this resistance on the outcome of patients hospitalized for CAP, empirically treated with betalactams, has not been evaluated in a randomized study. We conducted a prospective, randomized trial to assess the efficacy of amoxicillin-clavulanate (2 g/200 mg/8 hr) and ceftriaxone (1 g/24 hr) in a cohort of patients hospitalized for moderate-to-severe CAP. Three-hundred seventy-eight patients were randomized to receive amoxicillin-clavulanate (184 patients) or ceftriaxone (194 patients). Efficacy was assessed on Day 2, after completion of therapy and at long term follow-up. There were no significant differences in outcomes between treatment groups, both in intention-to-treat and per-protocol analysis. Overall mortality was 10.3% for amoxicillin-clavulanate and 8.8% for ceftriaxone (NS). There were 116 evaluable patients with proven pneumococcal pneumonia. Rates of high-level penicillin resistance (MIC of penicillin ≥2 µg/mL) were similar in the two groups (8.2 and 10.2%). Clinical efficacy at the end of therapy was 90.6% for amoxicillin-clavulanate and 88.9% for ceftriaxone (95% C.I. of the difference: -9.3 to +12.7%). No differences in outcomes were attributable to differences in penicillin susceptibility of pneumococcal strains. Sequential i.v./oral amoxicillin-clavulanate and parenteral ceftriaxone were equally safe and effective for the empirical treatment of acute bacterial pneumonia, including penicillin and cephalosporin-resistant pneumococcal pneumonia. The use of appropriate betalactams in patients with penumococcal pneumonia and in the overall CAP population, is reliable at the current level of resistance

Rainfall is a risk factor for sporadic cases of Legionella pneumophila Pneumonia

It is not known whether rainfall increases the risk of sporadic cases of Legionella pneumonia. We sought to test this hypothesis in a prospective observational cohort study of non-immunosuppressed adults hospitalized for community-acquired pneumonia (1995-2011). Cases with Legionella pneumonia were compared with those with non-Legionella pneumonia. Using daily rainfall data obtained from the regional meteorological service we examined patterns of rainfall over the days prior to admission in each study group. Of 4168 patients, 231 (5.5%) had Legionella pneumonia. The diagnosis was based on one or more of the following: sputum (41 cases), antigenuria (206) and serology (98). Daily rainfall average was 0.556 liters/m2 in the Legionella pneumonia group vs. 0.328 liters/m2 for non-Legionella pneumonia cases (p = 0.04). A ROC curve was plotted to compare the incidence of Legionella pneumonia and the weighted median rainfall. The cut-off point was 0.42 (AUC 0.54). Patients who were admitted to hospital with a prior weighted median rainfall higher than 0.42 were more likely to have Legionella pneumonia (OR 1.35; 95% CI 1.02-1.78; p = .03). Spearman Rho correlations revealed a relationship between Legionella pneumonia and rainfall average during each two-week reporting period (0.14; p = 0.003). No relationship was found between rainfall average and non-Legionella pneumonia cases (−0.06; p = 0.24). As a conclusion, rainfall is a significant risk factor for sporadic Legionella pneumonia. Physicians should carefully consider Legionella pneumonia when selecting diagnostic tests and antimicrobial therapy for patients presenting with CAP after periods of rainfall.

Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial

Introduction The benefit of corticosteroids as adjunctive treatment in patients with severe community-acquired pneumonia (CAP) requiring hospital admission remains unclear. This study aimed to evaluate the impact of corticosteroid treatment on outcomes in patients with CAP. Methods This was a prospective, double-blind and randomized study. All patients received treatment with ceftriaxone plus levofloxacin and methyl-prednisolone (MPDN) administered randomly and blindly as an initial bolus, followed by a tapering regimen, or placebo. Results Of the 56 patients included in the study, 28 (50%) were treated with concomitant corticosteroids. Patients included in the MPDN group show a more favourable evolution of the pO2/FiO2 ratio and faster decrease of fever, as well as greater radiological improvement at seven days. The time to resolution of morbidity was also significantly shorter in this group. Six patients met the criteria for mechanical ventilation (MV): five in the placebo group (22.7%) and one in the MPDN group (4.3%). The duration of MV was 13 days (interquartile range 7 to 26 days) for the placebo group and three days for the only case in the MPDN group. The differences did not reach statistical significance. Interleukin (IL)-6 and C-reactive protein (CRP) showed a significantly quicker decrease after 24 h of treatment among patients treated with MPDN. No differences in mortality were found among groups. Conclusions MPDN treatment, in combination with antibiotics, improves respiratory failure and accelerates the timing of clinical resolution of severe CAP needing hospital admission.